The National Institute for Food and Drug Surveillance (Invima), through its Medicines Room, has already approved the Sanitary Authorization for Emergency Use (Asue) for the Application of the Moderna vaccine for immunization against COVID-19 in children from six months to five years.
In resolution 2023001963, of January 19, 2023, the authorization was made official. The document indicates that the dosage in the concentration for the population between the six months and five years of age should be 0.10 mg/ml.
“In this sense, for the initial guideline, two doses of 25 micrograms each should be applied and, in the case of immunocompromised children, a dose of 25 micrograms”, reported Invima.
The health authority recommends administer the second dose 28 days after the first; and if the child turns six between his first and second doses, the latter must be the same as the first.
“This announcement is an important advance to continue facing the pandemic and achieve immunity in all population groups that need it most, such as the pediatric population. With this vaccine, in case of being infected, children will be safer, since vaccination significantly reduces the likelihood of developing serious illness, health complications, and hospitalizations associated with the virus.” said Diego Rodríguez, medical manager of Tecnofarma Colombia.
Likewise, the doctor emphasized the importance of vaccination in minors in order to achieve herd immunity.
“The pediatric population is an important vaccination target because it is the most exposed population and because we need to achieve herd immunity, which It will only be possible if the children are included in the vaccination days”, Rodriguez concluded.
You can see: Elevated or underground metro in Bogotá?
